BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20510316)

  • 21. Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.
    Cui J; Li C; Wang L; Wang C; Yang H; Li Y; Zhang L; Zhang L; Guo W; Liang M
    Int J Pharm; 2009 Feb; 368(1-2):24-30. PubMed ID: 18973800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal doxorubicin.
    Tardi PG; Boman NL; Cullis PR
    J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
    Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD
    Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
    Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
    Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes.
    Abdelbary G
    Pharm Dev Technol; 2011 Feb; 16(1):44-56. PubMed ID: 20025433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.
    Deniz A; Sade A; Severcan F; Keskin D; Tezcaner A; Banerjee S
    Biosci Rep; 2010 Jun; 30(5):365-73. PubMed ID: 19900165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxil®--the first FDA-approved nano-drug: lessons learned.
    Barenholz Y
    J Control Release; 2012 Jun; 160(2):117-34. PubMed ID: 22484195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of azathioprine encapsulation into liposomes.
    Gulati M; Grover M; Singh M; Singh S
    J Microencapsul; 1998; 15(4):485-94. PubMed ID: 9651870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes.
    Peer D; Margalit R
    Arch Biochem Biophys; 2000 Nov; 383(2):185-90. PubMed ID: 11185552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of adriamycin against a liver metastatic model by encapsulation in liposomes.
    Yachi K; Suzuki N; Tanaka N; Okada K; Mitsui I; Kawato Y; Komagata Y; Komiyama K; Kikuchi H
    Biopharm Drug Dispos; 1996 Nov; 17(8):699-715. PubMed ID: 8950048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposil, a promising composite material for drug storage and release.
    Bégu S; Aubert Pouëssel A; Lerner DA; Tourné-Péteilh C; Devoisselle JM
    J Control Release; 2007 Mar; 118(1):1-6. PubMed ID: 17250924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
    Abraham SA; Edwards K; Karlsson G; Hudon N; Mayer LD; Bally MB
    J Control Release; 2004 May; 96(3):449-61. PubMed ID: 15120901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation and characterization of modified lipid nanoparticles for doxorubicin controlled release.
    Ying XY; Du YZ; Chen WW; Yuan H; Hu FQ
    Pharmazie; 2008 Dec; 63(12):878-82. PubMed ID: 19177903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
    Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
    J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese.
    Chiu GN; Abraham SA; Ickenstein LM; Ng R; Karlsson G; Edwards K; Wasan EK; Bally MB
    J Control Release; 2005 May; 104(2):271-88. PubMed ID: 15907579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
    Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
    Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biopharmaceutical evaluation of the liposomes prepared by rehydration of freeze-dried empty liposomes (FDELs) with an aqueous solution of a drug.
    Yachi K; Harashima H; Kikuchi H; Sudo R; Yamauchi H; Ebihara K; Matsuo H; Funato K; Kiwada H
    Biopharm Drug Dispos; 1996 Oct; 17(7):589-605. PubMed ID: 8894117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes.
    Zhao XB; Muthusamy N; Byrd JC; Lee RJ
    J Pharm Sci; 2007 Sep; 96(9):2424-35. PubMed ID: 17588260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.